disease,drug,num_trials,primary_pos_trials,safety_flag_trials,conclusion,nct_ids,normalized_drug,is_gold_indication,is_gold_contraindication
Amyotrophic lateral sclerosis or motor neuron disease,BIIB105,1,0,0,证据不足,NCT04494256,biib105,0,0
Amyotrophic lateral sclerosis or motor neuron disease,deferiprone,1,0,0,证据不足,NCT02880033,deferiprone,0,0
Amyotrophic lateral sclerosis or motor neuron disease,dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg,1,0,0,证据不足,NCT00573443,dextromethorphan + quinidine,1,0
Amyotrophic lateral sclerosis or motor neuron disease,dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg,1,1,0,适应症线索,NCT00573443,dextromethorphan + quinidine,1,0
Amyotrophic lateral sclerosis or motor neuron disease,escitalopram,1,1,0,适应症线索,NCT00965497,escitalopram,1,0
Amyotrophic lateral sclerosis or motor neuron disease,FLX-787-ODT (orally disintigrating tablet),1,0,0,证据不足,NCT03338114,flx-787-odt,0,0
Amyotrophic lateral sclerosis or motor neuron disease,leuprolide,1,0,0,证据不足,NCT00004771,leuprolide,0,0
Amyotrophic lateral sclerosis or motor neuron disease,MediCabilis CBD Oil,1,0,0,证据不足,NCT03690791,medicabilis cbd oil,0,0
Amyotrophic lateral sclerosis or motor neuron disease,Psilocybin therapy,1,0,0,证据不足,NCT06782724,psilocybin therapy,0,0
Amyotrophic lateral sclerosis or motor neuron disease,testosterone,1,0,0,证据不足,NCT00004771,testosterone,0,0
Amyotrophic lateral sclerosis or motor neuron disease,"TPN-101, 400 mg/day",1,0,0,证据不足,NCT04993755,tpn-101,0,0
Arrhythmogenic Right Ventricular Cardiomyopathy,Anti-arrhythmic Drugs (AADs),1,0,0,证据不足,NCT05524077,anti-arrhythmic drugs,0,0
Arrhythmogenic Right Ventricular Cardiomyopathy,Avotermin,1,0,0,证据不足,NCT00627536,avotermin,0,0
Arrhythmogenic Right Ventricular Cardiomyopathy,flecainide iv,1,0,0,证据不足,NCT02302274,flecainide iv,0,0
Arrhythmogenic Right Ventricular Cardiomyopathy,Flecainide Pill,1,1,0,适应症线索,NCT03685149,flecainide pill,1,0
Arrhythmogenic Right Ventricular Cardiomyopathy,"Juvista (avotermin) plus placebo, standard-care (within-subject controls)",1,0,0,证据不足,NCT00594581,juvista plus placebo + standard-care,0,0
Arrhythmogenic Right Ventricular Cardiomyopathy,Spironolactone,1,0,0,证据不足,NCT03593317,spironolactone,0,0
Arrhythmogenic Right Ventricular Cardiomyopathy,Tideglusib,1,0,0,证据不足,NCT06174220,tideglusib,0,0
Atypical haemolytic uraemic syndrome,CCX168,2,0,0,证据不足,NCT02464891|NCT06004947,ccx168,0,0
Atypical haemolytic uraemic syndrome,Celecoxib,1,0,0,证据不足,NCT06004947,celecoxib,0,0
Atypical haemolytic uraemic syndrome,cemdisiran,1,0,0,证据不足,NCT03999840,cemdisiran,0,0
Atypical haemolytic uraemic syndrome,Cemdisiran,1,0,0,证据不足,NCT03303313,cemdisiran,0,0
Atypical haemolytic uraemic syndrome,Crovalimab,2,0,0,证据不足,NCT04861259|NCT04958265,crovalimab,0,0
Atypical haemolytic uraemic syndrome,Eculizumab,7,3,0,适应症线索,NCT00844545|NCT00844844|NCT01193348|NCT01194973|NCT01757431|NCT03518203|NCT05876351,eculizumab,1,0
Atypical haemolytic uraemic syndrome,eculizumab,3,0,0,证据不足,NCT00838513|NCT00844428|NCT02574403,eculizumab,1,0
Atypical haemolytic uraemic syndrome,Elizaria®,1,0,0,证据不足,NCT04749810,elizaria®,0,0
Atypical haemolytic uraemic syndrome,Iptacopan,2,0,0,证据不足,NCT04889430|NCT05935215,iptacopan,0,0
Atypical haemolytic uraemic syndrome,Iptcaopan 200 mg,1,0,0,证据不足,NCT05795140,iptcaopan,0,0
Atypical haemolytic uraemic syndrome,Itraconazole,1,0,0,证据不足,NCT06004947,itraconazole,0,0
Atypical haemolytic uraemic syndrome,Midazolam,1,0,0,证据不足,NCT06004947,midazolam,0,0
Atypical haemolytic uraemic syndrome,NM8074,1,0,0,证据不足,NCT05684159,nm8074,0,0
Atypical haemolytic uraemic syndrome,Placebos,1,0,0,证据不足,NCT03999840,placebos,0,0
Atypical haemolytic uraemic syndrome,Renin angiotensin system blockers,1,0,0,证据不足,NCT05726916,renin angiotensin system blockers,0,0
Atypical haemolytic uraemic syndrome,Rifampicin,1,0,0,证据不足,NCT06004947,rifampicin,0,0
Atypical haemolytic uraemic syndrome,Soliris®,1,0,0,证据不足,NCT05726916,soliris®,0,0
Atypical haemolytic uraemic syndrome,Spacing of Eculizumab infusions,1,0,0,证据不足,NCT04859608,spacing of eculizumab infusions,0,0
Atypical haemolytic uraemic syndrome,Ultomiris,1,0,0,证据不足,NCT06312644,ultomiris,0,0
Epileptic encephalopathy,0.5mg elsunersen,1,0,0,证据不足,NCT07019922,elsunersen,0,0
Epileptic encephalopathy,1.0mg/kg/day PRAX-562,1,0,0,证据不足,NCT07010471,day prax-562 + kg,0,0
Epileptic encephalopathy,1.5mg/kg/day PRAX-562,1,0,0,证据不足,NCT07010471,day prax-562 + kg,0,0
Epileptic encephalopathy,1mg elsunersen,1,0,0,证据不足,NCT07019922,elsunersen,0,0
Epileptic encephalopathy,Anti-epileptic drugs,1,0,0,证据不足,NCT02056236,anti-epileptic drugs,0,0
Epileptic encephalopathy,Anti-seizure medication,1,1,0,适应症线索,NCT03138876,anti-seizure medication,1,0
Epileptic encephalopathy,BMB-101,1,0,0,证据不足,NCT06401538,bmb-101,0,0
Epileptic encephalopathy,"Cannabis, Medical",1,0,0,证据不足,NCT03944447,cannabis + medical,0,0
Epileptic encephalopathy,CanniMed® 1:20,1,0,0,证据不足,NCT03024827,cannimed® 1:20,0,0
Epileptic encephalopathy,Cysteamine Bitartrate,2,0,0,证据不足,NCT02023866|NCT02473445,cysteamine,0,0
Epileptic encephalopathy,Enzalutamide,1,0,0,证据不足,NCT04290611,enzalutamide,0,0
Epileptic encephalopathy,ETX101,2,0,0,证据不足,NCT05419492|NCT06112275,etx101,0,0
Epileptic encephalopathy,Fenfluramine,1,0,0,证据不足,NCT05232630,fenfluramine,0,0
Epileptic encephalopathy,ganaxolone,1,0,1,禁忌信号,NCT03572933,ganaxolone,0,1
Epileptic encephalopathy,gene therapy,1,0,0,证据不足,NCT06983158,gene therapy,0,0
Epileptic encephalopathy,Glycerol Phenylbutyrate 1100 MG/ML [Ravicti],1,0,0,证据不足,NCT04937062,glycerol phenylbutyrate + ml [ravicti],0,0
Epileptic encephalopathy,Ketogenic diet,1,0,0,证据不足,NCT06700811,ketogenic diet,0,0
Epileptic encephalopathy,Levetiracetam,1,0,0,证据不足,NCT02603991,levetiracetam,0,0
Epileptic encephalopathy,LP352,5,0,0,证据不足,NCT05364021|NCT06149663|NCT06660394|NCT06719141|NCT06908226,lp352,0,0
Epileptic encephalopathy,"LP352, bexicaserin",1,0,0,证据不足,NCT05626634,bexicaserin + lp352,0,0
Epileptic encephalopathy,Matching Placebo,2,1,0,适应症线索,NCT02682927|NCT02926898,matching placebo,1,0
Epileptic encephalopathy,melatonin,1,0,0,证据不足,NCT01370486,melatonin,0,0
Epileptic encephalopathy,Memantine Hydrochloride 10 mg,1,0,0,证据不足,NCT03779672,memantine,0,0
Epileptic encephalopathy,NBI-827104,2,0,0,证据不足,NCT04625101|NCT05301894,nbi-827104,0,0
Epileptic encephalopathy,NBI-921352,2,0,0,证据不足,NCT04873869|NCT05226780,nbi-921352,0,0
Epileptic encephalopathy,OMT-28,1,0,0,证据不足,NCT05972954,omt-28,0,0
Epileptic encephalopathy,PRAX-222 - Fixed Doses,1,0,0,证据不足,NCT05737784,prax-222 - fixed doses,0,0
Epileptic encephalopathy,PRAX-222 - Initial Ascending Doses,1,0,0,证据不足,NCT05737784,prax-222 - initial ascending doses,0,0
Epileptic encephalopathy,PRAX-222 - Initial Dose,1,0,0,证据不足,NCT05737784,prax-222 - initial dose,0,0
Epileptic encephalopathy,PRAX-222 - Optional Ascending Doses,1,0,0,证据不足,NCT05737784,prax-222 - optional ascending doses,0,0
Epileptic encephalopathy,PRAX-562,1,0,0,证据不足,NCT05818553,prax-562,0,0
Epileptic encephalopathy,Rufinamide,1,0,0,证据不足,NCT02175173,rufinamide,0,0
Epileptic encephalopathy,Soticlestat,1,0,0,证据不足,NCT03635073,soticlestat,0,0
Epileptic encephalopathy,Stiripentol,1,0,0,证据不足,NCT02239276,stiripentol,0,0
Epileptic encephalopathy,Stiripentol capsule (Diacomit®),1,0,0,证据不足,NCT07176832,stiripentol capsule (diacomit®),0,0
Epileptic encephalopathy,Stiripentol oral suspension (Diacomit®),1,0,0,证据不足,NCT07176832,stiripentol oral suspension (diacomit®),0,0
Epileptic encephalopathy,STK-001,1,0,0,证据不足,NCT04740476,stk-001,0,0
Epileptic encephalopathy,STK-001 - Multiple Ascending Doses,1,0,0,证据不足,NCT04442295,stk-001 - multiple ascending doses,0,0
Epileptic encephalopathy,STK-001 - Single Ascending Doses,1,0,0,证据不足,NCT04442295,stk-001 - single ascending doses,0,0
Epileptic encephalopathy,TAK-935,2,1,0,适应症线索,NCT03166215|NCT03650452,tak-935,1,0
Epileptic encephalopathy,TSHA-105,1,0,0,证据不足,NCT07102524,tsha-105,0,0
Epileptic encephalopathy,Vatiquinone,1,0,0,证据不足,NCT04378075,vatiquinone,0,0
Epileptic encephalopathy,XEN496,2,0,0,证据不足,NCT04639310|NCT04912856,xen496,0,0
Epileptic encephalopathy,Zinc Acetate Dihydrate,1,0,0,证据不足,NCT06412653,zinc dihydrate,0,0
Epileptic encephalopathy,zorevunersen,1,0,0,证据不足,NCT06872125,zorevunersen,0,0
Epileptic encephalopathy,ZX008 (Fenfluramine Hydrochloride),5,1,1,可能适应症且需注意安全,NCT02682927|NCT02823145|NCT02926898|NCT03299842|NCT03936777,zx008,1,0
Gastrointestinal epithelial barrier disorders,pentoxifylline,1,0,0,证据不足,NCT01542268,pentoxifylline,0,0
Gastrointestinal epithelial barrier disorders,pentoxifylline placebo,1,0,0,证据不足,NCT01542268,pentoxifylline placebo,0,0
Gastrointestinal epithelial barrier disorders,Teduglutide,1,1,1,可能适应症且需注意安全,NCT02431325,teduglutide,1,0
Generalised pustular psoriasis,Adalimumab,1,0,0,证据不足,NCT02533375,adalimumab,0,0
Generalised pustular psoriasis,"After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.",1,0,0,证据不足,NCT06391996,after exclusion of relevant contraindications + participants received subcutaneous ustekinumab + secukinumab therapy.,0,0
Generalised pustular psoriasis,Brodalumab 210mg SC,1,0,0,证据不足,NCT04183881,brodalumab sc,0,0
Generalised pustular psoriasis,Certolizumab Pegol,1,1,1,可能适应症且需注意安全,NCT03051217,certolizumab pegol,1,0
Generalised pustular psoriasis,Deucravacitinib,1,0,0,证据不足,NCT06952465,deucravacitinib,0,0
Generalised pustular psoriasis,Guselkumab,1,0,0,证据不足,NCT02343744,guselkumab,0,0
Generalised pustular psoriasis,HB0034,3,0,0,证据不足,NCT05512598|NCT06231381|NCT06477536,hb0034,0,0
Generalised pustular psoriasis,Imsidolimab high dose,1,0,0,证据不足,NCT05352893,imsidolimab high dose,0,0
Generalised pustular psoriasis,Imsidolimab low dose,1,0,0,证据不足,NCT05352893,imsidolimab low dose,0,0
Generalised pustular psoriasis,Infliximab [infliximab biosimilar 3],1,0,0,证据不足,NCT03885089,infliximab [infliximab biosimilar 3],0,0
Generalised pustular psoriasis,Ixekizumab,1,0,0,证据不足,NCT03942042,ixekizumab,0,0
Generalised pustular psoriasis,JNJ-77242113,1,0,0,证据不足,NCT06295692,jnj-77242113,0,0
Generalised pustular psoriasis,KHK4827,1,0,0,证据不足,NCT01782937,khk4827,0,0
Generalised pustular psoriasis,KHK4827 140mg SC,1,0,0,证据不足,NCT02052609,khk4827 sc,0,0
Generalised pustular psoriasis,KHK4827 210mg SC,1,0,0,证据不足,NCT02052609,khk4827 sc,0,0
Generalised pustular psoriasis,risankizumab,1,0,0,证据不足,NCT03022045,risankizumab,0,0
Generalised pustular psoriasis,Spesolimab,6,2,1,可能适应症且需注意安全,NCT02978690|NCT03782792|NCT03886246|NCT04399837|NCT05670821|NCT06013969,spesolimab,1,0
Generalised pustular psoriasis,spesolimab,2,0,0,证据不足,NCT05200247|NCT05239039,spesolimab,1,0
Generalised pustular psoriasis,Spevigo®,1,0,0,证据不足,NCT06886009,spevigo®,0,0
Generalised pustular psoriasis,TAK-279,1,0,0,证据不足,NCT06323356,tak-279,0,0
Generalised pustular psoriasis,TQH2929 Injection,1,0,0,证据不足,NCT06433531,tqh2929 injection,0,0
Juvenile dermatomyositis,3 MPDN pulse + PDN,1,0,0,证据不足,NCT00323960,3 mpdn pulse + pdn,0,0
Juvenile dermatomyositis,3 MPDN pulse + PDN + CSA,1,0,0,证据不足,NCT00323960,3 mpdn pulse + csa + pdn,0,0
Juvenile dermatomyositis,3 MPDN pulse + PDN + MTX,1,0,0,证据不足,NCT00323960,3 mpdn pulse + mtx + pdn,0,0
Juvenile dermatomyositis,Abatacept,1,0,0,证据不足,NCT02594735,abatacept,0,0
Juvenile dermatomyositis,Abatacept subcutaneous,1,0,0,证据不足,NCT02971683,abatacept subcutaneous,0,0
Juvenile dermatomyositis,Adalimumab,1,0,0,证据不足,NCT07138898,adalimumab,0,0
Juvenile dermatomyositis,Alendronate,1,0,0,证据不足,NCT00277251,alendronate,0,0
Juvenile dermatomyositis,Anti-CD19 UCAR-T cells,1,0,0,证据不足,NCT06686524,anti-cd19 ucar-t cells,0,0
Juvenile dermatomyositis,Azathioprine,1,0,0,证据不足,NCT07138898,azathioprine,0,0
Juvenile dermatomyositis,Baricitinib,2,0,0,证据不足,NCT01724580|NCT05524311,baricitinib,0,0
Juvenile dermatomyositis,Certolizumab,1,0,0,证据不足,NCT07138898,certolizumab,0,0
Juvenile dermatomyositis,Continue IS (MMF or MPA),1,0,1,禁忌信号,NCT05000216,continue is,0,1
Juvenile dermatomyositis,Continue IS (MTX),1,0,1,禁忌信号,NCT05000216,continue is,0,1
Juvenile dermatomyositis,Cyclosporine,1,0,0,证据不足,NCT07138898,cyclosporine,0,0
Juvenile dermatomyositis,denosumab,1,0,0,证据不足,NCT02418273,denosumab,0,0
Juvenile dermatomyositis,Descartes-08,1,0,0,证据不足,NCT07089121,descartes-08,0,0
Juvenile dermatomyositis,Deucravacitinb,1,0,0,证据不足,NCT07012057,deucravacitinb,0,0
Juvenile dermatomyositis,Etanercept,2,0,0,证据不足,NCT00035958|NCT07138898,etanercept,0,0
Juvenile dermatomyositis,Golimumab,1,0,0,证据不足,NCT07138898,golimumab,0,0
Juvenile dermatomyositis,H.P. Acthar Gel,1,1,0,适应症线索,NCT02245841,h.p. acthar gel,1,0
Juvenile dermatomyositis,Hydroxychloroquine,1,0,0,证据不足,NCT07138898,hydroxychloroquine,0,0
Juvenile dermatomyositis,Infliximab,1,0,0,证据不足,NCT07138898,infliximab,0,0
Juvenile dermatomyositis,Leflunomide,1,0,0,证据不足,NCT07138898,leflunomide,0,0
Juvenile dermatomyositis,Methotrexate,2,0,0,证据不足,NCT00035958|NCT07138898,methotrexate,0,0
Juvenile dermatomyositis,Methylprednisolone,1,0,0,证据不足,NCT00004357,methylprednisolone,0,0
Juvenile dermatomyositis,Mycophenolate,1,0,0,证据不足,NCT07138898,mycophenolate,0,0
Juvenile dermatomyositis,Prednisolone,1,0,0,证据不足,NCT00004357,prednisolone,0,0
Juvenile dermatomyositis,Prednisone,1,0,0,证据不足,NCT00035958,prednisone,0,0
Juvenile dermatomyositis,Rituximab,1,0,0,证据不足,NCT00106184,rituximab,0,0
Juvenile dermatomyositis,Sodium Thiosulfate,1,0,0,证据不足,NCT03267277,sodium thiosulfate,0,0
Juvenile dermatomyositis,Sodium thiosulfate,1,0,0,证据不足,NCT01572844,sodium thiosulfate,0,0
Juvenile dermatomyositis,Sulfasalazine,1,0,0,证据不足,NCT07138898,sulfasalazine,0,0
Juvenile dermatomyositis,Tacrolimus,1,0,0,证据不足,NCT07138898,tacrolimus,0,0
Juvenile dermatomyositis,Tofacitinib,1,0,0,证据不足,NCT07138898,tofacitinib,0,0
Juvenile dermatomyositis,Upadacitinib,1,0,0,证据不足,NCT07138898,upadacitinib,0,0
Juvenile dermatomyositis,Withhold IS (B cell depletion therapy),1,0,0,证据不足,NCT05000216,withhold is,0,1
Juvenile dermatomyositis,Withhold IS (MMF or MPA),1,0,1,禁忌信号,NCT05000216,withhold is,0,1
Juvenile dermatomyositis,Withhold IS (MTX),1,0,1,禁忌信号,NCT05000216,withhold is,0,1
Lactic acidosis,Abacavir,1,0,0,证据不足,NCT00143702,abacavir,0,0
Lactic acidosis,Albuterol,1,0,0,证据不足,NCT02073747,albuterol,0,0
Lactic acidosis,"cofactor supplementation (thiamine, riboflavin, L-carnitine)",1,0,0,证据不足,NCT00202228,cofactor supplementation (thiamine + l-carnitine) + riboflavin,0,0
Lactic acidosis,Control,1,0,0,证据不足,NCT01973504,control,0,0
Lactic acidosis,Cysteamine Bitartrate,1,0,0,证据不足,NCT02473445,cysteamine,0,0
Lactic acidosis,d4T,1,0,0,证据不足,NCT00143702,d4t,0,0
Lactic acidosis,Dichloroacetate,4,0,0,证据不足,NCT00015015|NCT00031161|NCT00068913|NCT01797276,dichloroacetate,1,0
Lactic acidosis,Dichloroacetate (DCA),1,1,0,适应症线索,NCT00874276,dichloroacetate,1,0
Lactic acidosis,Efavirenz,1,0,0,证据不足,NCT00023218,efavirenz,0,0
Lactic acidosis,"entecavir, lamivudine",1,0,0,证据不足,NCT01354652,entecavir + lamivudine,0,0
Lactic acidosis,Fenoldopam mesilate,1,0,0,证据不足,NCT00747331,fenoldopam mesilate,0,0
Lactic acidosis,Glycerol Tributyrate,1,0,0,证据不足,NCT06792500,glycerol tributyrate,0,0
Lactic acidosis,Haloperidol or olanzapine,1,0,0,证据不足,NCT01139463,haloperidol or olanzapine,0,0
Lactic acidosis,Idebenone,1,0,0,证据不足,NCT00887562,idebenone,0,0
Lactic acidosis,Insulin,1,0,0,证据不足,NCT00124826,insulin,0,0
Lactic acidosis,IW-6463 Tablets,1,0,0,证据不足,NCT04475549,iw-6463 tablets,0,0
Lactic acidosis,Lopinavir/Ritonavir,1,0,0,证据不足,NCT00023218,lopinavir + ritonavir,0,0
Lactic acidosis,Magnesium Sulfate,1,0,0,证据不足,NCT03466528,magnesium,0,0
Lactic acidosis,Metformin,4,0,0,证据不足,NCT01873859|NCT02848508|NCT04762966|NCT04766008,metformin,0,0
Lactic acidosis,MP4OX,3,0,0,证据不足,NCT01004198|NCT01262196|NCT01973504,mp4ox,0,0
Lactic acidosis,Nitisinone (NTBC),1,0,0,证据不足,NCT00031161,nitisinone,0,0
Lactic acidosis,Nitroglycerin infusion,1,1,0,适应症线索,NCT01901419,nitroglycerin infusion,1,0
Lactic acidosis,Normal Saline,1,0,0,证据不足,NCT02073747,normal saline,0,0
Lactic acidosis,OMT-28,1,0,0,证据不足,NCT05972954,omt-28,0,0
Lactic acidosis,Oral administration of 100 mg KH176 twice daily,1,0,0,证据不足,NCT04604548,oral administration of kh176 twice daily,0,0
Lactic acidosis,Pabrinex,1,0,0,证据不足,NCT03466528,pabrinex,0,0
Lactic acidosis,Placebos,1,0,0,证据不足,NCT03122678,placebos,0,0
Lactic acidosis,Riboflavin and Thiamine (Supplementation),1,0,0,证据不足,NCT00143702,riboflavin + thiamine,0,0
Lactic acidosis,Ringers Lactate solution,1,0,0,证据不足,NCT01004198,ringers lactate solution,0,0
Lactic acidosis,Saline,1,0,0,证据不足,NCT01262196,saline,0,0
Lactic acidosis,sodium dichloroacetate,2,0,0,证据不足,NCT00004490|NCT00004493,sodium dichloroacetate,0,0
Lactic acidosis,Sonlicromanol,1,0,0,证据不足,NCT06451757,sonlicromanol,0,0
Lactic acidosis,Thiamine,2,0,0,证据不足,NCT02974257|NCT03122678,thiamine,0,0
Lactic acidosis,TTI-0102,1,0,0,证据不足,NCT06644534,tti-0102,0,0
Lactic acidosis,Vitamin B1-ratiopharm,1,0,0,证据不足,NCT01524315,vitamin b1-ratiopharm,0,0
Lactic acidosis,zagociguat 15mg,2,0,0,证据不足,NCT06402123|NCT06961344,zagociguat,0,0
Lactic acidosis,zagociguat 30mg,1,0,0,证据不足,NCT06402123,zagociguat,0,0
Neonatal cholestasis,3 mg [14C]-A4250 capsule,1,0,0,证据不足,NCT03082937,[14c]-a4250 capsule,0,0
Neonatal cholestasis,4-Phenylbutyrate,1,0,0,证据不足,NCT04531878,4-phenylbutyrate,0,0
Neonatal cholestasis,A4250,1,0,0,证据不足,NCT02963077,a4250,0,0
Neonatal cholestasis,Cholic Acids,1,0,0,证据不足,NCT00007020,cholic acids,0,0
Neonatal cholestasis,Clinolipid,2,0,0,证据不足,NCT02476994|NCT04555044,clinolipid,0,0
Neonatal cholestasis,CRC (A3384),1,0,0,证据不足,NCT02963077,crc,0,0
Neonatal cholestasis,Intralipid,3,0,0,证据不足,NCT01373918|NCT02476994|NCT04555044,intralipid,0,0
Neonatal cholestasis,"Intralipid, 20% Intravenous Emulsion",1,0,0,证据不足,NCT03387579,20% intravenous emulsion + intralipid,0,0
Neonatal cholestasis,Livmarli,1,0,0,证据不足,NCT06193928,livmarli,0,0
Neonatal cholestasis,LUM001,2,0,1,禁忌信号,NCT01903460|NCT02057692,lum001,1,1
Neonatal cholestasis,LUM001 (Maralixibat),3,1,0,适应症线索,NCT02047318|NCT02117713|NCT02160782,lum001,1,1
Neonatal cholestasis,magnesium gluconate,1,0,0,证据不足,NCT00007033,magnesium gluconate,0,0
Neonatal cholestasis,magnesium sulfate,1,0,0,证据不足,NCT00007033,magnesium,0,0
Neonatal cholestasis,Maralixibat,1,0,0,证据不足,NCT04729751,maralixibat,0,0
Neonatal cholestasis,maralixibat,1,0,0,证据不足,NCT04530994,maralixibat,0,0
Neonatal cholestasis,Meropenem Injection,1,0,0,证据不足,NCT04370145,meropenem injection,0,0
Neonatal cholestasis,N-Acetylcysteine,1,0,0,证据不足,NCT06260566,n-acetylcysteine,0,0
Neonatal cholestasis,Odevixibat,2,1,1,可能适应症且需注意安全,NCT04674761|NCT05035030,odevixibat,1,0
Neonatal cholestasis,Omegaven,2,0,0,证据不足,NCT02370251|NCT03072667,omegaven,0,0
Neonatal cholestasis,Questran,1,0,0,证据不足,NCT02963077,questran,0,0
Neonatal cholestasis,sincalide,1,0,0,证据不足,NCT00004414,sincalide,0,0
Neonatal cholestasis,SMOFlipid,1,0,0,证据不足,NCT02721277,smoflipid,0,0
Neonatal cholestasis,Smoflipid 20% Lipid Emulsion for Injection,1,0,0,证据不足,NCT03387579,smoflipid 20% lipid emulsion for injection,0,0
Neonatal cholestasis,Sulperazon,1,0,0,证据不足,NCT04370145,sulperazon,0,0
Neonatal cholestasis,TAK-625,1,0,0,证据不足,NCT05543174,tak-625,0,0
Neonatal cholestasis,Teicoplanin,1,0,0,证据不足,NCT04370145,teicoplanin,0,0
Neonatal cholestasis,Ursodiol,1,0,0,证据不足,NCT00846963,ursodiol,0,0
Neonatal cholestasis,ursodiol,1,0,0,证据不足,NCT00004315,ursodiol,0,0
Neurotransmitter disorders,"(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)",1,0,0,证据不足,NCT06511908,(2r + 6r)-hydroxynorketamine (0.25 to + kg),0,0
Neurotransmitter disorders,[68Ga]RM2,1,0,0,证据不足,NCT02483884,[68ga]rm2,0,0
Neurotransmitter disorders,Active Aprepitant,1,0,0,证据不足,NCT01204723,active aprepitant,0,0
Neurotransmitter disorders,APH-1501,1,0,0,证据不足,NCT03813095,aph-1501,0,0
Neurotransmitter disorders,Aripiprazole,1,0,0,证据不足,NCT01710163,aripiprazole,0,0
Neurotransmitter disorders,BNC,1,0,0,证据不足,NCT01747213,bnc,0,0
Neurotransmitter disorders,Clonidine,1,0,0,证据不足,NCT03396588,clonidine,0,0
Neurotransmitter disorders,Comparator,1,0,0,证据不足,NCT02227368,comparator,0,0
Neurotransmitter disorders,CX516 (Ampalex),1,0,0,证据不足,NCT00001662,cx516,0,0
Neurotransmitter disorders,Desloratadine,1,1,1,可能适应症且需注意安全,NCT01916967,desloratadine,1,0
Neurotransmitter disorders,Desloratadine 5 mg,1,0,0,证据不足,NCT01918033,desloratadine,1,0
Neurotransmitter disorders,Detemir,1,0,0,证据不足,NCT01239550,detemir,0,0
Neurotransmitter disorders,Dextroamphetamine,1,0,0,证据不足,NCT02634684,dextroamphetamine,0,0
Neurotransmitter disorders,Diltiazem,1,0,0,证据不足,NCT02695992,diltiazem,0,0
Neurotransmitter disorders,Doxazosin,1,0,0,证据不足,NCT01953432,doxazosin,0,0
Neurotransmitter disorders,Duloxetine,1,0,0,证据不足,NCT04178993,duloxetine,0,0
Neurotransmitter disorders,Escitalopram,2,1,0,适应症线索,NCT01728194|NCT05389046,escitalopram,1,0
Neurotransmitter disorders,Escitalopram+Aripiprazole,1,0,0,证据不足,NCT05389046,aripiprazole + escitalopram,0,0
Neurotransmitter disorders,Escitalopram+Aripiprazole+omega-3 PUFAs,1,0,0,证据不足,NCT05389046,aripiprazole + escitalopram + omega-3 pufas,0,0
Neurotransmitter disorders,Escitalopram+omega-3 PUFAs,1,0,0,证据不足,NCT05389046,escitalopram + omega-3 pufas,0,0
Neurotransmitter disorders,Guanfacine Extended Release,1,0,0,证据不足,NCT05657860,guanfacine extended release,0,0
Neurotransmitter disorders,Icatibant (30 mg),1,0,0,证据不足,NCT02045264,icatibant (),0,0
Neurotransmitter disorders,Intravenous Ketamine,1,0,0,证据不足,NCT05991232,intravenous ketamine,0,0
Neurotransmitter disorders,INVEGA SUSTENNA,1,0,0,证据不足,NCT04922593,invega sustenna,0,0
Neurotransmitter disorders,Ketamine,2,0,0,证据不足,NCT02577250|NCT04032301,ketamine,0,0
Neurotransmitter disorders,Ketorolac 10 Mg Oral Tablet,1,0,0,证据不足,NCT06150898,ketorolac oral tablet,0,0
Neurotransmitter disorders,KuvanTM Therapy,1,1,0,适应症线索,NCT00688844,kuvantm therapy,1,0
Neurotransmitter disorders,Latanoprost 0.005% Ophthalmic Solution,1,0,0,证据不足,NCT04412096,latanoprost 0.005% ophthalmic solution,0,0
Neurotransmitter disorders,lidocaine infusion,1,0,0,证据不足,NCT04622904,lidocaine infusion,0,0
Neurotransmitter disorders,lidocaine-ketamine infusion,1,0,0,证据不足,NCT04622904,lidocaine-ketamine infusion,0,0
Neurotransmitter disorders,lidocaine-magnesium infusion,1,0,0,证据不足,NCT04622904,lidocaine-magnesium infusion,0,0
Neurotransmitter disorders,Lithium,1,0,0,证据不足,NCT01710163,lithium,0,0
Neurotransmitter disorders,LY03005,3,0,0,证据不足,NCT03357796|NCT03733574|NCT03822065,ly03005,0,0
Neurotransmitter disorders,"LY03010 156 mg treatment group, deltoid",1,0,0,证据不足,NCT05321602,deltoid + ly03010 treatment group,0,0
Neurotransmitter disorders,"LY03010 156 mg treatment group, gluteal",1,0,0,证据不足,NCT05321602,gluteal + ly03010 treatment group,0,0
Neurotransmitter disorders,"LY03010 351 mg treatment group, deltoid",1,0,0,证据不足,NCT05321602,deltoid + ly03010 treatment group,0,0
Neurotransmitter disorders,"LY03010 351 mg treatment group, gluteal",1,0,0,证据不足,NCT05321602,gluteal + ly03010 treatment group,0,0
Neurotransmitter disorders,LY03010; paliperidone palmitate,1,0,0,证据不足,NCT04922593,ly03010; paliperidone palmitate,0,0
Neurotransmitter disorders,MDMA,1,0,0,证据不足,NCT05138068,mdma,0,0
Neurotransmitter disorders,Methamphetamine,1,0,0,证据不足,NCT04178993,methamphetamine,0,0
Neurotransmitter disorders,Methylphenidate,1,0,0,证据不足,NCT04178993,methylphenidate,0,0
Neurotransmitter disorders,Metoprolol,1,0,0,证据不足,NCT02695992,metoprolol,0,0
Neurotransmitter disorders,Metoprolol XL,1,0,0,证据不足,NCT01049009,metoprolol xl,0,0
Neurotransmitter disorders,Midazolam,1,0,0,证据不足,NCT05610969,midazolam,0,0
Neurotransmitter disorders,Modafinil and PET (brain imaging),1,0,0,证据不足,NCT00701532,modafinil + pet,0,0
Neurotransmitter disorders,Morphine,1,0,0,证据不足,NCT03396588,morphine,0,0
Neurotransmitter disorders,Morphine Sulfate,1,0,0,证据不足,NCT05143424,morphine,0,0
Neurotransmitter disorders,Nebivolol,1,0,0,证据不足,NCT01049009,nebivolol,0,0
Neurotransmitter disorders,nebulized ketamine,1,0,0,证据不足,NCT06752759,nebulized ketamine,0,0
Neurotransmitter disorders,Omeprazole 20mg Capsule,1,0,0,证据不足,NCT06150898,omeprazole capsule,0,0
Neurotransmitter disorders,Placebo Aprepitant,1,0,0,证据不足,NCT01204723,placebo aprepitant,0,0
Neurotransmitter disorders,Placebo oral capsule,1,0,0,证据不足,NCT04178993,placebo oral capsule,0,0
Neurotransmitter disorders,Posiphen,1,0,1,禁忌信号,NCT04524351,posiphen,0,1
Neurotransmitter disorders,Pregabalin 75mg,1,0,0,证据不足,NCT06150898,pregabalin,0,0
Neurotransmitter disorders,Pristiq,2,0,0,证据不足,NCT03357796|NCT03733574,pristiq,0,0
Neurotransmitter disorders,Ropinirole Implant,1,0,0,证据不足,NCT03250117,ropinirole implant,0,0
Neurotransmitter disorders,Ropinirole oral product,1,0,0,证据不足,NCT03250117,ropinirole oral product,0,0
Neurotransmitter disorders,sapropterin dihydrochloride,1,0,0,证据不足,NCT01274026,sapropterin dihydrochloride,0,0
Neurotransmitter disorders,SGS-742,1,0,1,禁忌信号,NCT02019667,sgs-742,0,1
Neurotransmitter disorders,Sodium Benzoate 2gram/day,1,0,0,证据不足,NCT06340789,day + sodium benzoate 2gram,0,0
Neurotransmitter disorders,Ticagrelor,1,0,0,证据不足,NCT02227368,ticagrelor,0,0
Neurotransmitter disorders,Timolol 0.5% ophthalmic solution,1,0,0,证据不足,NCT04412096,timolol 0.5% ophthalmic solution,0,0
Neurotransmitter disorders,Tizanidine,1,0,0,证据不足,NCT06666673,tizanidine,0,0
Neurotransmitter disorders,VTS-K,1,0,0,证据不足,NCT05615948,vts-k,0,0
Non-CF bronchiectasis,7% Hypertonic Saline via nebulization,1,0,0,证据不足,NCT06242795,7% hypertonic saline via nebulization,0,0
Non-CF bronchiectasis,ALX-009,1,0,0,证据不足,NCT02598999,alx-009,0,0
Non-CF bronchiectasis,An'ningpai,1,0,0,证据不足,NCT04511897,an'ningpai,0,0
Non-CF bronchiectasis,AZLI,2,1,2,可能适应症且需注意安全,NCT01313624|NCT01314716,azli,1,0
Non-CF bronchiectasis,BAY85-8501,1,0,0,证据不足,NCT01818544,bay85-8501,0,0
Non-CF bronchiectasis,bLF,1,0,0,证据不足,NCT02598999,blf,0,0
Non-CF bronchiectasis,Brensocatib 10 mg,1,1,1,可能适应症且需注意安全,NCT03218917,brensocatib,1,0
Non-CF bronchiectasis,Brensocatib 25 mg,1,1,0,适应症线索,NCT03218917,brensocatib,1,0
Non-CF bronchiectasis,CHF 6333,1,0,0,证据不足,NCT04010799,chf 6333,0,0
Non-CF bronchiectasis,Cholecalciferol (vitaminD3),1,0,0,证据不足,NCT04411901,cholecalciferol,0,0
Non-CF bronchiectasis,Ciprofloxacin (BAYQ3939) dry powder for inhalation,1,0,0,证据不足,NCT02106832,ciprofloxacin dry powder for inhalation,0,0
Non-CF bronchiectasis,Ciprofloxacin dispersion for inhalation,2,0,0,证据不足,NCT01515007|NCT02104245,ciprofloxacin dispersion for inhalation,0,0
Non-CF bronchiectasis,Ciprofloxacin DPI (BAYQ3939),1,1,0,适应症线索,NCT01764841,ciprofloxacin dpi,1,0
Non-CF bronchiectasis,inhaled corticosteroid therapy,1,0,0,证据不足,NCT02714283,inhaled corticosteroid therapy,0,0
Non-CF bronchiectasis,LABA/LAMA or Placebo inhalation,1,0,0,证据不足,NCT04509661,laba + lama or placebo inhalation,0,0
Non-CF bronchiectasis,macrolide therapy,1,0,0,证据不足,NCT02714283,macrolide therapy,0,0
Non-CF bronchiectasis,Nebulized 5% Hypertonic saline,1,0,0,证据不足,NCT04765033,nebulized 5% hypertonic saline,0,0
Non-CF bronchiectasis,Oral roflumilast,1,0,0,证据不足,NCT03428334,oral roflumilast,0,0
Non-CF bronchiectasis,OSCN-,1,0,0,证据不足,NCT02598999,oscn-,0,0
Non-CF bronchiectasis,Roflumilast Oral Tablet,1,0,0,证据不足,NCT04322929,roflumilast oral tablet,0,0
Non-CF bronchiectasis,S-1226,1,0,0,证据不足,NCT03903913,s-1226,0,0
Non-CF bronchiectasis,Saline 0.9% inhalation solution,1,0,0,证据不足,NCT02657473,saline 0.9% inhalation solution,0,0
Non-CF bronchiectasis,tobramycin inhalation solution,1,0,0,证据不足,NCT02657473,tobramycin inhalation solution,0,0
Non-CF bronchiectasis,Xenon,1,0,0,证据不足,NCT04793867,xenon,0,0
Noonan syndrome,BR790+anlotinib,1,0,0,证据不足,NCT05715398,anlotinib + br790,0,0
Noonan syndrome,Capmatinib,1,0,0,证据不足,NCT02587650,capmatinib,0,0
Noonan syndrome,Ceritinib,1,0,0,证据不足,NCT02587650,ceritinib,0,0
Noonan syndrome,Cetuximab,1,0,0,证据不足,NCT04670679,cetuximab,0,0
Noonan syndrome,Chemotherapeutic Agent,1,0,0,证据不足,NCT05566795,chemotherapeutic agent,0,0
Noonan syndrome,Cobimetinib,1,0,0,证据不足,NCT03989115,cobimetinib,0,0
Noonan syndrome,Drug: Osimertinib,1,0,0,证据不足,NCT03989115,drug: osimertinib,0,0
Noonan syndrome,Entrectinib,1,0,0,证据不足,NCT02587650,entrectinib,0,0
Noonan syndrome,ERAS-007,1,0,0,证据不足,NCT04959981,eras-007,0,0
Noonan syndrome,ERAS-601,2,0,0,证据不足,NCT04670679|NCT04959981,eras-601,0,0
Noonan syndrome,Human Growth Hormone,1,0,0,证据不足,NCT06668805,human growth hormone,0,0
Noonan syndrome,Irinotecan Hydrochloride,1,0,0,证据不足,NCT01787500,irinotecan,0,0
Noonan syndrome,JAB-3068,2,0,0,证据不足,NCT03518554|NCT03565003,jab-3068,0,0
Noonan syndrome,JAB-3312,2,0,0,证据不足,NCT04045496|NCT04121286,jab-3312,0,0
Noonan syndrome,Lamotrigine,1,0,0,证据不足,NCT03504501,lamotrigine,0,0
Noonan syndrome,"MAXOMAT ®, biosynthetic growth hormone",1,0,0,证据不足,NCT00452725,biosynthetic growth hormone + maxomat ®,0,0
Noonan syndrome,MEK162,2,0,0,证据不足,NCT01556568|NCT01885195,mek162,0,0
Noonan syndrome,Norditropin,1,0,0,证据不足,NCT05308927,norditropin,0,0
Noonan syndrome,Norditropin®,1,0,0,证据不足,NCT05330325,norditropin®,0,0
Noonan syndrome,Osimertinib,1,0,0,证据不足,NCT04959981,osimertinib,0,0
Noonan syndrome,Pembrolizumab,1,0,0,证据不足,NCT04670679,pembrolizumab,0,0
Noonan syndrome,Regorafenib,1,0,0,证据不足,NCT02587650,regorafenib,0,0
Noonan syndrome,rhIGF-1/rhIGFBP-3,1,0,0,证据不足,NCT00351221,rhigf-1 + rhigfbp-3,0,0
Noonan syndrome,RLY-1971,1,0,0,证据不足,NCT04252339,rly-1971,0,0
Noonan syndrome,RMC-4630,2,0,0,证据不足,NCT03634982|NCT03989115,rmc-4630,0,0
Noonan syndrome,Somapacitan,2,0,0,证据不足,NCT05330325|NCT05723835,somapacitan,0,0
Noonan syndrome,somatropin,4,1,0,适应症线索,NCT00960128|NCT01529840|NCT01529944|NCT01927861,somatropin,1,0
Noonan syndrome,Somatropin,1,0,0,证据不足,NCT03435627,somatropin,1,0
Noonan syndrome,Sotorasib,1,0,0,证据不足,NCT04959981,sotorasib,0,0
Noonan syndrome,Standard therapy,1,0,0,证据不足,NCT06555237,standard therapy,0,0
Noonan syndrome,TNO155,1,0,0,证据不足,NCT03114319,tno155,0,0
Noonan syndrome,TNO155 in combination with EGF816 (nazartinib),1,0,0,证据不足,NCT03114319,tno155 in combination with egf816,0,0
Noonan syndrome,Tovorafenib,1,0,0,证据不足,NCT05566795,tovorafenib,0,0
Noonan syndrome,Trametinib tablet,1,0,0,证据不足,NCT06555237,trametinib tablet,0,0
Noonan syndrome,Vemurafenib,1,0,0,证据不足,NCT01787500,vemurafenib,0,0
Noonan syndrome,Vosoritide,1,0,0,证据不足,NCT04219007,vosoritide,0,0
Noonan syndrome,Vosoritide Injection,1,0,0,证据不足,NCT06668805,vosoritide injection,0,0
Osteogenesis imperfecta,AGA2115,2,0,0,证据不足,NCT06086613|NCT07062588,aga2115,0,0
Osteogenesis imperfecta,Alendronate,2,0,0,证据不足,NCT00159419|NCT02303873,alendronate,0,0
Osteogenesis imperfecta,Alternative osteoporosis medications,1,0,0,证据不足,NCT03638128,alternative osteoporosis medications,0,0
Osteogenesis imperfecta,Bisphosphonate,2,0,0,证据不足,NCT05768854|NCT05972551,bisphosphonate,0,0
Osteogenesis imperfecta,bisphosphonates,1,0,0,证据不足,NCT04115774,bisphosphonates,0,0
Osteogenesis imperfecta,Bone marrow-derived mesenchymal stromal cells (MSCs),1,0,0,证据不足,NCT05559801,bone marrow-derived mesenchymal stromal cells,0,0
Osteogenesis imperfecta,BPS804,2,0,0,证据不足,NCT01417091|NCT03216486,bps804,0,0
Osteogenesis imperfecta,Busulfan,1,0,0,证据不足,NCT00705120,busulfan,0,0
Osteogenesis imperfecta,Collagen-PVP,1,0,0,证据不足,NCT04019782,collagen-pvp,0,0
Osteogenesis imperfecta,Cyclophosphamide,1,0,0,证据不足,NCT00705120,cyclophosphamide,0,0
Osteogenesis imperfecta,Cyclosporin,1,0,0,证据不足,NCT00705120,cyclosporin,0,0
Osteogenesis imperfecta,Denosumab,3,0,0,证据不足,NCT01799798|NCT02352753|NCT03638128,denosumab,0,0
Osteogenesis imperfecta,Fresolimumab,1,0,0,证据不足,NCT03064074,fresolimumab,0,0
Osteogenesis imperfecta,Humatrope,1,0,0,证据不足,NCT00001305,humatrope,0,0
Osteogenesis imperfecta,pamidronate,1,0,0,证据不足,NCT00655681,pamidronate,0,0
Osteogenesis imperfecta,Pamidronate,1,0,0,证据不足,NCT00159419,pamidronate,0,0
Osteogenesis imperfecta,Pamidronate (Aredia),1,0,0,证据不足,NCT00005901,pamidronate,0,0
Osteogenesis imperfecta,Placebos,1,0,0,证据不足,NCT00131469,placebos,0,0
Osteogenesis imperfecta,RhPDGF-BB,1,0,0,证据不足,NCT06632418,rhpdgf-bb,0,0
Osteogenesis imperfecta,Risedronate Oral Tablet,1,0,0,证据不足,NCT04152551,risedronate oral tablet,0,0
Osteogenesis imperfecta,Risedronate Sodium,1,0,0,证据不足,NCT03208582,risedronate sodium,1,0
Osteogenesis imperfecta,risedronate sodium (Actonel),1,1,0,适应症线索,NCT00106028,risedronate sodium,1,0
Osteogenesis imperfecta,Romosozumab,2,0,0,证据不足,NCT04545554|NCT05972551,romosozumab,0,0
Osteogenesis imperfecta,SAR439459,1,0,0,证据不足,NCT05231668,sar439459,0,0
Osteogenesis imperfecta,setrusumab,1,1,1,可能适应症且需注意安全,NCT03118570,setrusumab,1,0
Osteogenesis imperfecta,Teriparatide,1,0,0,证据不足,NCT01679080,teriparatide,0,0
Osteogenesis imperfecta,Teriparatide (FORTEO),1,0,0,证据不足,NCT00131469,teriparatide,0,0
Osteogenesis imperfecta,Teriparatide Pen Injector,1,0,0,证据不足,NCT03735537,teriparatide pen injector,0,0
Osteogenesis imperfecta,Tranexamic acid,1,0,0,证据不足,NCT05321199,tranexamic acid,0,0
Osteogenesis imperfecta,Zoledronic Acid,5,0,0,证据不足,NCT00063479|NCT00131118|NCT00982124|NCT03169192|NCT03735537,zoledronic acid,0,0
Osteogenesis imperfecta,Zoledronic acid,1,0,0,证据不足,NCT01679080,zoledronic acid,0,0
Osteogenesis imperfecta,zoledronic acid (optional),1,0,0,证据不足,NCT03118570,zoledronic acid,0,0
Primary ciliary dyskinesia,Albuterol,1,1,0,适应症线索,NCT04901715,albuterol,1,0
Primary ciliary dyskinesia,Hypertonic Saline,1,0,0,证据不足,NCT02871778,hypertonic saline,0,0
Primary ciliary dyskinesia,Ivacaftor,1,0,1,禁忌信号,NCT02871778,ivacaftor,0,1
Primary ciliary dyskinesia,Placebo (0.17% saline),1,0,0,证据不足,NCT02871778,placebo (0.17% saline),0,0
Primary ciliary dyskinesia,RCT1100,3,0,0,证据不足,NCT05737485|NCT06600425|NCT06633757,rct1100,0,0
Primary ciliary dyskinesia,Salbutamol,1,0,0,证据不足,NCT05932316,salbutamol,0,0
Primary ciliary dyskinesia,VX-371,1,1,1,可能适应症且需注意安全,NCT02871778,vx-371,1,0
Primary ciliary dyskinesia,VX-371 + HS,1,0,0,证据不足,NCT02871778,hs + vx-371,0,0
Primary lymphoedema,Chemotherapy,1,1,0,适应症线索,NCT00589121,chemotherapy,1,0
Primary lymphoedema,Propranolol,1,0,0,证据不足,NCT02595996,propranolol,0,0
Primary membranoproliferative glomerulonephritis,Aliskiren,1,0,0,证据不足,NCT04183101,aliskiren,0,0
Primary membranoproliferative glomerulonephritis,ALXN1720,1,0,0,证据不足,NCT05314231,alxn1720,0,0
Primary membranoproliferative glomerulonephritis,APL-2,1,0,0,证据不足,NCT03453619,apl-2,0,0
Primary membranoproliferative glomerulonephritis,Avacopan,1,0,1,禁忌信号,NCT03301467,avacopan,0,1
Primary membranoproliferative glomerulonephritis,Avacopan Matching Placebo,1,0,0,证据不足,NCT03301467,avacopan matching placebo,0,0
Primary membranoproliferative glomerulonephritis,BCX9930,1,0,0,证据不足,NCT05162066,bcx9930,0,0
Primary membranoproliferative glomerulonephritis,Belimumab Injection,1,0,0,证据不足,NCT03747159,belimumab injection,0,0
Primary membranoproliferative glomerulonephritis,CDX-1135,1,0,0,证据不足,NCT01791686,cdx-1135,0,0
Primary membranoproliferative glomerulonephritis,Cyclosporin,1,0,0,证据不足,NCT03180723,cyclosporin,0,0
Primary membranoproliferative glomerulonephritis,Danicopan,3,0,0,证据不足,NCT03124368|NCT03369236|NCT03459443,danicopan,0,0
Primary membranoproliferative glomerulonephritis,Daratumumab,1,0,0,证据不足,NCT03095118,daratumumab,0,0
Primary membranoproliferative glomerulonephritis,Eculizumab,2,0,0,证据不足,NCT01221181|NCT02093533,eculizumab,0,0
Primary membranoproliferative glomerulonephritis,Enalapril,1,0,0,证据不足,NCT04183101,enalapril,0,0
Primary membranoproliferative glomerulonephritis,iptacopan,1,0,0,证据不足,NCT05755386,iptacopan,0,0
Primary membranoproliferative glomerulonephritis,LNP023,1,0,0,证据不足,NCT03955445,lnp023,0,0
Primary membranoproliferative glomerulonephritis,Pegcetacoplan,4,1,1,可能适应症且需注意安全,NCT04572854|NCT04729062|NCT05067127|NCT05809531,pegcetacoplan,1,0
Primary membranoproliferative glomerulonephritis,Rituximab,2,0,0,证据不足,NCT00275613|NCT03180723,rituximab,0,0
Primary membranoproliferative glomerulonephritis,SGB-9768,1,0,0,证据不足,NCT06786338,sgb-9768,0,0
Severe hypertriglyceridaemia,AKR-963,1,0,0,证据不足,NCT01229566,akr-963,0,0
Severe hypertriglyceridaemia,ARI-3037MO,1,0,0,证据不足,NCT02250105,ari-3037mo,0,0
Severe hypertriglyceridaemia,ARO-APOC3,2,0,0,证据不足,NCT03783377|NCT04720534,aro-apoc3,0,0
Severe hypertriglyceridaemia,CaPre,2,0,0,证据不足,NCT03361501|NCT03398005,capre,0,0
Severe hypertriglyceridaemia,CAT-2003,1,0,0,证据不足,NCT01968720,cat-2003,0,0
Severe hypertriglyceridaemia,conservative treatment,1,0,0,证据不足,NCT02622854,conservative treatment,0,0
Severe hypertriglyceridaemia,Corn Oil,1,0,0,证据不足,NCT02625870,corn oil,0,0
Severe hypertriglyceridaemia,DR10624 Injection,1,0,0,证据不足,NCT06555640,dr10624 injection,0,0
Severe hypertriglyceridaemia,Epanova,2,1,0,适应症线索,NCT02009865|NCT02189252,epanova,1,0
Severe hypertriglyceridaemia,Epanova (4 g) and Lovaza (4 g),1,0,0,证据不足,NCT01208961,epanova () + lovaza (),0,0
Severe hypertriglyceridaemia,Ethyl Icosapentate,1,0,0,证据不足,NCT04239950,ethyl icosapentate,0,0
Severe hypertriglyceridaemia,Evinacumab,1,0,0,证据不足,NCT06500598,evinacumab,0,1
Severe hypertriglyceridaemia,evinacumab,2,0,2,禁忌信号,NCT03452228|NCT04863014,evinacumab,0,1
Severe hypertriglyceridaemia,Fenofibrate,4,0,0,证据不足,NCT01594983|NCT03001817|NCT03011450|NCT05883865,fenofibrate,0,0
Severe hypertriglyceridaemia,Fish Oil,1,0,0,证据不足,NCT01594983,fish oil,0,0
Severe hypertriglyceridaemia,Gemcabene,1,1,1,可能适应症且需注意安全,NCT02944383,gemcabene,1,0
Severe hypertriglyceridaemia,Insulin,1,0,0,证据不足,NCT03501680,insulin,0,0
Severe hypertriglyceridaemia,ISIS apoC-III Rx,1,0,0,证据不足,NCT01529424,isis apoc-iii rx,0,0
Severe hypertriglyceridaemia,K-877,2,2,0,适应症线索,NCT03001817|NCT03011450,k-877,1,0
Severe hypertriglyceridaemia,LCQ908,2,0,0,证据不足,NCT01146522|NCT01594983,lcq908,0,0
Severe hypertriglyceridaemia,Lovaza,1,0,0,证据不足,NCT02189252,lovaza,0,0
Severe hypertriglyceridaemia,Lovaza (4 g) and Epanova (4 g),1,0,0,证据不足,NCT01208961,epanova () + lovaza (),0,0
Severe hypertriglyceridaemia,MAT9001 (omega-3 pentaenoic acid),1,0,0,证据不足,NCT04662528,mat9001,0,0
Severe hypertriglyceridaemia,Metformin Eicosapentaenoate,1,0,0,证据不足,NCT02113163,metformin eicosapentaenoate,0,0
Severe hypertriglyceridaemia,Metformin HCl and Vascepa,1,0,0,证据不足,NCT02113163,metformin hcl + vascepa,0,0
Severe hypertriglyceridaemia,mibavademab,1,0,0,证据不足,NCT06548100,mibavademab,0,0
Severe hypertriglyceridaemia,Olezarsen,5,0,0,证据不足,NCT05079919|NCT05355402|NCT05552326|NCT05610280|NCT05681351,olezarsen,0,0
Severe hypertriglyceridaemia,Olive Oil,1,1,0,适应症线索,NCT02009865,olive oil,1,0
Severe hypertriglyceridaemia,omefas,1,1,1,可能适应症且需注意安全,NCT01242527,omefas,1,0
Severe hypertriglyceridaemia,Omega-3-Acid Ethyl Esters 90 Soft Capsules,1,0,0,证据不足,NCT02625870,omega-3-acid ethyl esters 90 soft capsules,0,0
Severe hypertriglyceridaemia,Pegozafermin,2,1,1,可能适应症且需注意安全,NCT04541186|NCT05852431,pegozafermin,1,0
Severe hypertriglyceridaemia,Placebo (for Fenofibrate),1,0,0,证据不足,NCT03001817,placebo,0,0
Severe hypertriglyceridaemia,Placebo (for K-877),2,0,0,证据不足,NCT03001817|NCT03011450,placebo,0,0
Severe hypertriglyceridaemia,Placebo of fenofibrate,1,0,0,证据不足,NCT01594983,placebo of fenofibrate,0,0
Severe hypertriglyceridaemia,Placebo of fish oil,1,0,0,证据不足,NCT01594983,placebo of fish oil,0,0
Severe hypertriglyceridaemia,Placebo of LCQ908,1,0,0,证据不足,NCT01594983,placebo of lcq908,0,0
Severe hypertriglyceridaemia,Plozasiran,1,0,0,证据不足,NCT06880770,plozasiran,0,0
Severe hypertriglyceridaemia,Plozasiran Injection,2,0,0,证据不足,NCT06347003|NCT06347016,plozasiran injection,0,0
Severe hypertriglyceridaemia,SC401B 2 capsules,1,0,0,证据不足,NCT01997268,sc401b 2 capsules,0,0
Severe hypertriglyceridaemia,SC401B 4 capsules,1,0,0,证据不足,NCT01997268,sc401b 4 capsules,0,0
Severe hypertriglyceridaemia,SC401B 6 capsules,1,0,0,证据不足,NCT01997268,sc401b 6 capsules,0,0
Severe hypertriglyceridaemia,sterile normal saline (0.9% NaCl),1,0,0,证据不足,NCT03783377,sterile normal saline (0.9% nacl),0,0
